Patents
More topics under "C07D - Heterocyclic compounds" (1,537,440)
C07D 201 - Preparation, separation, purification, or stabilisation of unsubstituted lactams (2,192)
C07D 203 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom (1,097)
C07D 205 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom (6,868)
C07D 207 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom (40,304)
C07D 209 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom (45,780)
C07D 211 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings (37,939)
C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members (63,273)
C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems (27,676)
C07D 217 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems (11,865)
C07D 219 - Heterocyclic compounds containing acridine or hydrogenated acridine ring systems (2,120)
C07D 221 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups (10,931)
C07D 223 - Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom (8,732)
C07D 225 - Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom (1,649)
C07D 227 - Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups (473)
C07D 229 - Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms (515)
C07D 231 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings (25,550)
C07D 233 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings (34,408)
C07D 235 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings (15,325)
C07D 237 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings (8,468)
C07D 239 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings (42,619)
C07D 241 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings (18,673)
C07D 243 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms (5,961)
C07D 245 - Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms (898)
C07D 247 - Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups (239)
C07D 249 - Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms (17,749)
C07D 251 - Heterocyclic compounds containing 1,3,5-triazine rings (10,913)
C07D 253 - Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group (2,967)
C07D 255 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups (739)
C07D 257 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms (9,612)
C07D 259 - Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms (488)
C07D 261 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings (11,459)
C07D 263 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings (20,978)
C07D 265 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms (11,132)
C07D 267 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms (2,022)
C07D 269 - Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups (111)
C07D 271 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms (7,144)
C07D 273 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups (2,368)
C07D 275 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings (4,972)
C07D 277 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings (33,621)
C07D 279 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms (5,149)
C07D 281 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms (1,924)
C07D 283 - Heterocyclic compounds containing rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms, according to more than one of groups (102)
C07D 285 - Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups (9,964)
C07D 291 - Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms (1,087)
C07D 293 - Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms (553)
C07D 295 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms (34,005)
C07D 301 - Preparation of oxiranes (10,136)
C07D 303 - Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom (12,512)
C07D 305 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms (5,442)
C07D 307 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom (47,108)
C07D 309 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings (12,815)
C07D 311 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings (24,127)
C07D 313 - Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom (3,580)
C07D 315 - Heterocyclic compounds containing rings having one oxygen atom as the only ring hetero atom according to more than one of groups (1,360)
C07D 317 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms (18,224)
C07D 319 - Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms (10,283)
C07D 321 - Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups (2,079)
C07D 323 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms (1,581)
C07D 325 - Heterocyclic compounds containing rings having oxygen as the only ring hetero atom according to more than one of groups (168)
C07D 327 - Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms (2,428)
C07D 329 - Heterocyclic compounds containing rings having oxygen and selenium or oxygen and tellurium atoms as the only ring hetero atoms (47)
C07D 331 - Heterocyclic compounds containing rings of less than five members, having one sulfur atom as the only ring hetero atom (456)
C07D 333 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom (32,883)
C07D 335 - Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom (4,725)
C07D 337 - Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom (875)
C07D 339 - Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms (3,352)
C07D 341 - Heterocyclic compounds containing rings having three or more sulfur atoms as the only ring hetero atoms (281)
C07D 343 - Heterocyclic compounds containing rings having sulfur and selenium or sulfur and tellurium atoms as the only ring hetero atoms (52)
C07D 345 - Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms (419)
C07D 347 - Heterocyclic compounds containing rings having halogen atoms as ring hetero atoms (38)
C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group (62,587)
C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom (69,397)
C07D 407 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group (11,963)
C07D 409 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms (52,226)
C07D 411 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms (2,465)
C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
C07D 415 - Heterocyclic compounds containing the thiamine skeleton (90)
C07D 417 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group (62,773)
C07D 419 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms (1,431)
C07D 421 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms (480)
C07D 451 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof (5,273)
C07D 453 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids (5,704)
C07D 455 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine (2,122)
C07D 457 - Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula: , e.g. lysergic acid (836)
C07D 459 - Heterocyclic compounds containing benz [g] indolo [2, 3-a] quinolizine ring systems, e.g. yohimbine; 16, 18-lactones thereof, e.g. reserpic acid lactone (97)
C07D 461 - Heterocyclic compounds containing indolo [3, 2, 1-d, e] pyrido [3, 2, 1-i, j] [1, 5]-naphthyridine ring systems, e.g. vincamine (286)
C07D 463 - Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (613)
C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups (64,559)
C07D 473 - Heterocyclic compounds containing purine ring systems (11,932)
C07D 475 - Heterocyclic compounds containing pteridine ring systems (2,718)
C07D 477 - Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (2,484)
C07D 487 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups (57,272)
C07D 489 - Heterocyclic compounds containing 4ah-8, 9 c- iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: (2,334)
C07D 491 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or (29,726)
C07D 493 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system (17,376)
C07D 495 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms (21,336)
C07D 497 - Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms (1,069)
C07D 498 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms (21,960)
C07D 499 - Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (3,448)
C07D 501 - Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (7,574)
C07D 503 - Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (648)
C07D 505 - Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (556)
C07D 507 - Heterocyclic compounds containing a condensed beta-lactam ring system, not provided for by groups , or; Such ring systems being further condensed (161)
C07D 513 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (15,120)
C07D 515 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (877)
C07D 517 - Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms (452)
C07D 519 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or (11,041)
C07D 521 - Heterocyclic compounds containing unspecified hetero rings (16,203)
Patents for C07D - Heterocyclic compounds (10,420)
03/2006
03/30/2006WO2005007624A3 Compositions of orthogonal glutamyl-trna and aminoacyl trna synthetase pairs and uses thereof
03/30/2006US20060069088 Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
03/30/2006CA2577818A1 New heterocyclic amides
03/29/2006EP1640361A2 Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst
03/29/2006EP1638931A2 Method of targeting a therapeutic agent
03/29/2006EP1492792B1 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino¬4,5-b|indole-1-acetamide derivatives, preparation and use thereof in medicaments
03/29/2006CN1753892A Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as HIV integrase inhibitors
03/29/2006CN1753877A Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor
03/29/2006CN1753673A Prodrugs of gaba analogs, compositions and uses thereof
03/28/2006US7019011 Aminoindazole derivatives as medicaments and pharmaceutical compositions including them
03/28/2006CA2290963C S-omeprazole magnesium trihydrate
03/28/2006CA2290392C Salts of optically active sulfoxide derivative
03/28/2006CA2153805C C10 taxane derivatives and pharmaceutical compositions
03/23/2006WO2006031179A1 Process for preparation of phtalimide
03/23/2006WO2005028434A3 Novel heterocyclic compounds as hsp90-inhibitors
03/23/2006WO2005023758A3 Process for the preparation of losartan potassium form i
03/23/2006WO2005007623A8 Inhibition of syk kinase expression
03/23/2006US20060063797 Process for preparing a substituted imidazopyridine compound
03/22/2006EP1636236A1 Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors
03/22/2006EP1636233A1 Cannabinoid receptor ligands and uses thereof
03/22/2006EP1636214A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
03/22/2006EP1636194A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
03/22/2006EP1636193A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
03/22/2006EP1436296B1 Process for the direct preparation of pyrrolo[3,4-c]pyrroles
03/22/2006EP1140840B1 -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
03/22/2006CN1751031A HIV replication inhibiting pyrimidines and triazines
03/22/2006CN1751030A HIV replication inhibiting pyrimidines and triazines
03/22/2006CN1749252A Compounds useful to treat retroviral infections
03/21/2006US7015237 Pyridine matrix metalloproteinase inhibitors
03/15/2006EP1633734A2 Mucin synthesis inhibitors
03/15/2006EP1633727A1 Improved production of the rosuvastatin calcium salt
03/15/2006EP1633717A1 New p2x7 receptor antagonists and their use
03/15/2006EP1633716A2 Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors
03/15/2006EP1633694A2 Substituted indoles and a process for preparing substituted indoles
03/15/2006EP1465864B1 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade
03/15/2006EP1448566B1 Chemokine receptor antagonists and methods of use thereof
03/15/2006CN1747940A Crystalline modifications of triazinylaminostilbenes
03/15/2006CN1245386C 1,2-dihydropyridine compounds, process for preparation of same and use thereof
03/14/2006CA2147984C Butenyl-substituted taxanes and composition
03/09/2006WO2006024699A1 Thioxothiazolidinone compounds for use as pharmaceuticals
03/09/2006US20060052611 Mitotic kinesin inhibitors
03/09/2006US20060052406 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
03/09/2006US20060052380 Novel compounds
03/08/2006EP1631147A2 Alkoxy alkylsulfanyl phenols
03/08/2006EP1404667B1 Piperidine derivatives useful as modulators of chemokine receptor activity
03/08/2006CN1743331A Process for preparing azacycloalkanoylaminothiazoles
03/08/2006CN1743302A Arylpiperazines having 5-hydroxyl-typtamine activity
03/08/2006CN1244579C Synthesis of 2-oxazolidone derivate by one still process
03/08/2006CN1244569C C-10 position taxane derivative and its medicine composition
03/02/2006WO2004052850A3 Methods and compounds producing dipeptidyl peptidase iv inhibitors and intermediates thereof
03/02/2006US20060046985 Tetrahydro--4h-pyrido[1,2-a}pyrimidines and related compounds useful as hiv integrase inhibitors
03/01/2006EP1628949A2 Process and intermediates for preparing benzazepines
03/01/2006EP1628649A2 Neuroprotective benzoate and benzamide compounds
03/01/2006EP1472255B1 Aza-arylpiperazines
03/01/2006EP1363910B1 Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
03/01/2006EP1345942B1 Pyrazinoquinoxaline derivatives as serotonin agonists and antagonists
03/01/2006EP1319007B1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
03/01/2006EP1233962B1 Novel heterocyclic compounds and their use as medicines
03/01/2006CN1741788A Ceramic based nanoparticles for entrapping therapeutic agents for photodynamic therapy and method of using same
03/01/2006CN1740168A Therapeutic benzopyranone compounds used as intermediates.
03/01/2006CN1243735C 2-lminopyrrolidine derivatives
03/01/2006CN1243723C N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors for FSAD
02/2006
02/28/2006US7005433 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
02/28/2006CA2347469C Esters of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 100,907
02/23/2006WO2006019353A1 Composition and method for the treatement of psoriasis
02/23/2006WO2006004507A3 New benzothiazole derivatives useful for treating cns disorders
02/23/2006WO2005058815A3 Ip-10 antibodies and their uses
02/23/2006WO2005003086A3 Sulfonic acid derivatives of polycyclic dyes used for analytical applications
02/23/2006US20060041132 Novel triazolo pyrimidine compounds
02/23/2006US20060041124 Process for preparing pyrrolotriazine kinase inhibitors
02/23/2006US20060041016 Composition and method for the treatment of psoriasis
02/23/2006US20060040945 Annellated pyrrole compounds as proton pump inhibitors for treating ulcer
02/23/2006US20060040939 Benzamide inhibitors of the P2X, receptor
02/22/2006EP1626964A2 New benzimidazole derivatives
02/22/2006EP1626960A1 Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists
02/22/2006CN1738825A Thienopyridazinones and their use in modulation of autoimmune disease
02/22/2006CN1738807A Substituted aralkyl derivatives
02/22/2006CN1738806A Oxo-azabicyclic compounds
02/22/2006CN1738801A Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
02/22/2006CN1736985A Growth hormone secretagogues
02/22/2006CN1243001C Method of manufacturing sertindole
02/22/2006CN1242813C Combination therapy for osteoporosis
02/21/2006US7002022 treatment of neoplastic diseases that respond to inhibition of the vascular endothelial growth factor receptor tyrosine kinase activity; tumors, retinopathy, macular degeneration
02/21/2006US7001909 For therapy of cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease
02/21/2006US7001908 Arylpiperazines having activity at the serotonin 1A receptor
02/21/2006US7001605 Composition for controlling harmful bio-organisms and method for controlling harmful bio-organisms using the same
02/21/2006CA2423825C New perindopril salt and pharmaceutical compounds containing it
02/16/2006WO2004094373A3 A method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
02/16/2006US20060035938 2-Pyridone derivatives as inhibitors of neutrophile elastase
02/16/2006US20060035885 8-Substituted-6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidin-4-one derivatives
02/15/2006EP1626048A1 Crystal of benzimidazole derivative and process for producing the same
02/15/2006CN1735673A Environmentally benign anti-icing or deicing fluids
02/15/2006CN1735613A 稠合杂环化合物 Fused heterocyclic compounds
02/15/2006CN1735596A Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
02/15/2006CN1733727A Crystalline carvedilol, processes for the manufacture thereof, pharmaceutical compositions and uses thereof
02/15/2006CN1733725A Process for preparing 2-iminopyrrolidine derivatives
02/15/2006CN1241924C Method for preparing enkephalinase and angiotensin-converting enzyme inhibitor intermediate and its intermediate
02/14/2006CA2374643C 1-trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives as substance p antagonists
02/14/2006CA2210044C 4-hydroxy-piperidine derivatives
02/09/2006WO2006014136A1 Piperidine derivatives as histamine h3 receptor ligands
1 ... 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 ... 105